CN115607510B - High-concentration oleanolic acid nanoemulsion composition and preparation method thereof - Google Patents
High-concentration oleanolic acid nanoemulsion composition and preparation method thereof Download PDFInfo
- Publication number
- CN115607510B CN115607510B CN202110419745.1A CN202110419745A CN115607510B CN 115607510 B CN115607510 B CN 115607510B CN 202110419745 A CN202110419745 A CN 202110419745A CN 115607510 B CN115607510 B CN 115607510B
- Authority
- CN
- China
- Prior art keywords
- extract
- oleanolic acid
- essential oil
- acid
- hair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 title claims abstract description 175
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 title claims abstract description 175
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 title claims abstract description 175
- 229940100243 oleanolic acid Drugs 0.000 title claims abstract description 175
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 title claims abstract description 175
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 title claims abstract description 174
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 118
- 239000000203 mixture Substances 0.000 title claims abstract description 88
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 239000000341 volatile oil Substances 0.000 claims abstract description 177
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 67
- 210000004209 hair Anatomy 0.000 claims abstract description 36
- 150000003505 terpenes Chemical class 0.000 claims abstract description 36
- 235000007586 terpenes Nutrition 0.000 claims abstract description 33
- 239000000839 emulsion Substances 0.000 claims abstract description 30
- 238000003756 stirring Methods 0.000 claims abstract description 30
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims abstract description 29
- 239000002537 cosmetic Substances 0.000 claims abstract description 27
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960003321 baicalin Drugs 0.000 claims abstract description 23
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims abstract description 23
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 claims abstract description 22
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 claims abstract description 22
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 22
- 235000011576 oleuropein Nutrition 0.000 claims abstract description 22
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 claims abstract description 22
- 239000004094 surface-active agent Substances 0.000 claims abstract description 21
- 239000000654 additive Substances 0.000 claims abstract description 19
- 238000002156 mixing Methods 0.000 claims abstract description 18
- 239000004064 cosurfactant Substances 0.000 claims abstract description 16
- 230000000996 additive effect Effects 0.000 claims abstract description 6
- 238000010008 shearing Methods 0.000 claims abstract description 3
- 239000000284 extract Substances 0.000 claims description 73
- -1 polyoxyethylene Polymers 0.000 claims description 37
- 201000004384 Alopecia Diseases 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 23
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 23
- 239000000499 gel Substances 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 244000246386 Mentha pulegium Species 0.000 claims description 22
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 22
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 22
- 239000010642 eucalyptus oil Substances 0.000 claims description 22
- 229940044949 eucalyptus oil Drugs 0.000 claims description 22
- 235000001050 hortel pimenta Nutrition 0.000 claims description 22
- 238000004945 emulsification Methods 0.000 claims description 19
- 244000165082 Lavanda vera Species 0.000 claims description 18
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 18
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 18
- 238000004090 dissolution Methods 0.000 claims description 18
- 150000004676 glycans Chemical class 0.000 claims description 18
- 239000001102 lavandula vera Substances 0.000 claims description 18
- 235000018219 lavender Nutrition 0.000 claims description 18
- 229920001282 polysaccharide Polymers 0.000 claims description 18
- 239000005017 polysaccharide Substances 0.000 claims description 18
- 241001061264 Astragalus Species 0.000 claims description 16
- 241000218645 Cedrus Species 0.000 claims description 16
- 235000006533 astragalus Nutrition 0.000 claims description 16
- 239000004359 castor oil Substances 0.000 claims description 16
- 235000019438 castor oil Nutrition 0.000 claims description 16
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 16
- 210000004233 talus Anatomy 0.000 claims description 16
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 15
- 239000012153 distilled water Substances 0.000 claims description 15
- 239000003921 oil Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims description 12
- 240000003553 Leptospermum scoparium Species 0.000 claims description 12
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 12
- 239000002562 thickening agent Substances 0.000 claims description 12
- 231100000360 alopecia Toxicity 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 11
- 239000003755 preservative agent Substances 0.000 claims description 11
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical group CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 201000002996 androgenic alopecia Diseases 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000006210 lotion Substances 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 8
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 8
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 8
- 235000019441 ethanol Nutrition 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 239000003906 humectant Substances 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 8
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 7
- 102000008186 Collagen Human genes 0.000 claims description 7
- 108010035532 Collagen Proteins 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 7
- 235000011399 aloe vera Nutrition 0.000 claims description 7
- 206010068168 androgenetic alopecia Diseases 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 229920001436 collagen Polymers 0.000 claims description 7
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims description 7
- 229960004039 finasteride Drugs 0.000 claims description 7
- 229960005150 glycerol Drugs 0.000 claims description 7
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 7
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 7
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 229960005323 phenoxyethanol Drugs 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- 239000002453 shampoo Substances 0.000 claims description 6
- 244000144927 Aloe barbadensis Species 0.000 claims description 5
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- 239000000051 antiandrogen Substances 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 239000003974 emollient agent Substances 0.000 claims description 5
- 235000016709 nutrition Nutrition 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 239000000419 plant extract Substances 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 4
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 claims description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims description 4
- 229940083980 lavender extract Drugs 0.000 claims description 4
- 235000020723 lavender extract Nutrition 0.000 claims description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 4
- 229940114496 olive leaf extract Drugs 0.000 claims description 4
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 229940032094 squalane Drugs 0.000 claims description 4
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 208000003024 Diffuse alopecia Diseases 0.000 claims description 3
- 241000628997 Flos Species 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- 235000008434 ginseng Nutrition 0.000 claims description 3
- 229940089161 ginsenoside Drugs 0.000 claims description 3
- 229930182494 ginsenoside Natural products 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 239000002304 perfume Substances 0.000 claims description 3
- 235000011007 phosphoric acid Nutrition 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 229960000502 poloxamer Drugs 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 230000001256 tonic effect Effects 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
- 241001116389 Aloe Species 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 241000195940 Bryophyta Species 0.000 claims description 2
- 241000050051 Chelone glabra Species 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 240000000774 Cunila origanoides Species 0.000 claims description 2
- 235000018274 Cunila origanoides Nutrition 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 235000014866 Dictamnus albus Nutrition 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Natural products CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 2
- RPWFJAMTCNSJKK-UHFFFAOYSA-N Dodecyl gallate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 RPWFJAMTCNSJKK-UHFFFAOYSA-N 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 235000015489 Emblica officinalis Nutrition 0.000 claims description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 2
- 240000008397 Ganoderma lucidum Species 0.000 claims description 2
- 241001071795 Gentiana Species 0.000 claims description 2
- 241000208680 Hamamelis mollis Species 0.000 claims description 2
- 229920002971 Heparan sulfate Polymers 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 239000009636 Huang Qi Substances 0.000 claims description 2
- 229920000288 Keratan sulfate Polymers 0.000 claims description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- 239000004166 Lanolin Substances 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims description 2
- 241000180649 Panax notoginseng Species 0.000 claims description 2
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 2
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 2
- 244000046146 Pueraria lobata Species 0.000 claims description 2
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 2
- 240000007164 Salvia officinalis Species 0.000 claims description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 2
- 244000274883 Urtica dioica Species 0.000 claims description 2
- 235000009108 Urtica dioica Nutrition 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 2
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 2
- 239000002250 absorbent Substances 0.000 claims description 2
- 230000002745 absorbent Effects 0.000 claims description 2
- 229960000458 allantoin Drugs 0.000 claims description 2
- 150000003863 ammonium salts Chemical group 0.000 claims description 2
- 239000009188 angelicae sinensis extract Substances 0.000 claims description 2
- 229960000271 arbutin Drugs 0.000 claims description 2
- 229960003121 arginine Drugs 0.000 claims description 2
- 229960002233 benzalkonium bromide Drugs 0.000 claims description 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 150000008366 benzophenones Chemical class 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- 229960000997 bicalutamide Drugs 0.000 claims description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 2
- 229940119217 chamomile extract Drugs 0.000 claims description 2
- 235000020221 chamomile extract Nutrition 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- 229960001380 cimetidine Drugs 0.000 claims description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 2
- 150000001851 cinnamic acid derivatives Chemical class 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 229960005188 collagen Drugs 0.000 claims description 2
- 229960003843 cyproterone Drugs 0.000 claims description 2
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 claims description 2
- 229960003067 cystine Drugs 0.000 claims description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 2
- 229960002887 deanol Drugs 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 235000010386 dodecyl gallate Nutrition 0.000 claims description 2
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 claims description 2
- 229960004199 dutasteride Drugs 0.000 claims description 2
- 235000019126 equol Nutrition 0.000 claims description 2
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 2
- 235000001785 ferulic acid Nutrition 0.000 claims description 2
- 229940114124 ferulic acid Drugs 0.000 claims description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 2
- 229940100242 glycol stearate Drugs 0.000 claims description 2
- 229940094952 green tea extract Drugs 0.000 claims description 2
- 235000020688 green tea extract Nutrition 0.000 claims description 2
- 239000000118 hair dye Substances 0.000 claims description 2
- OIKBVOIOVNEVJR-UHFFFAOYSA-N hexadecyl 6-methylheptanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(C)C OIKBVOIOVNEVJR-UHFFFAOYSA-N 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- 229940093629 isopropyl isostearate Drugs 0.000 claims description 2
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 2
- 229940039717 lanolin Drugs 0.000 claims description 2
- 235000019388 lanolin Nutrition 0.000 claims description 2
- 229960004400 levonorgestrel Drugs 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- 229960003646 lysine Drugs 0.000 claims description 2
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 claims description 2
- 229940053934 norethindrone Drugs 0.000 claims description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 2
- 229960001679 octinoxate Drugs 0.000 claims description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims description 2
- SWUARLUWKZWEBQ-VQHVLOKHSA-N phenethyl caffeate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-VQHVLOKHSA-N 0.000 claims description 2
- SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 claims description 2
- 229950005134 polycarbophil Drugs 0.000 claims description 2
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 claims description 2
- 235000010388 propyl gallate Nutrition 0.000 claims description 2
- 239000000473 propyl gallate Substances 0.000 claims description 2
- 229940075579 propyl gallate Drugs 0.000 claims description 2
- 229940064064 purslane extract Drugs 0.000 claims description 2
- 150000003244 quercetin derivatives Chemical class 0.000 claims description 2
- 235000005412 red sage Nutrition 0.000 claims description 2
- 229940092258 rosemary extract Drugs 0.000 claims description 2
- 235000020748 rosemary extract Nutrition 0.000 claims description 2
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 claims description 2
- 229940112950 sage extract Drugs 0.000 claims description 2
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 claims description 2
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims description 2
- 239000010018 saw palmetto extract Substances 0.000 claims description 2
- 229940063845 saw palmetto extract Drugs 0.000 claims description 2
- 229940057910 shea butter Drugs 0.000 claims description 2
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 claims description 2
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 claims description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 2
- 239000004289 sodium hydrogen sulphite Substances 0.000 claims description 2
- 239000001540 sodium lactate Substances 0.000 claims description 2
- 229940005581 sodium lactate Drugs 0.000 claims description 2
- 235000011088 sodium lactate Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 2
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 claims description 2
- 239000008513 turmeric extract Substances 0.000 claims description 2
- 229940052016 turmeric extract Drugs 0.000 claims description 2
- 235000020240 turmeric extract Nutrition 0.000 claims description 2
- 229940099259 vaseline Drugs 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 150000003700 vitamin C derivatives Chemical class 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 229940118846 witch hazel Drugs 0.000 claims description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 3
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 2
- 229960002446 octanoic acid Drugs 0.000 claims 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims 1
- 244000119298 Emblica officinalis Species 0.000 claims 1
- 244000018716 Impatiens biflora Species 0.000 claims 1
- 235000015912 Impatiens biflora Nutrition 0.000 claims 1
- 240000004371 Panax ginseng Species 0.000 claims 1
- 239000004721 Polyphenylene oxide Substances 0.000 claims 1
- 208000030695 Sparse hair Diseases 0.000 claims 1
- 235000005155 Tanacetum balsamita Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 claims 1
- 229960000452 diethylstilbestrol Drugs 0.000 claims 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 1
- 229920000570 polyether Polymers 0.000 claims 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 1
- 229960003415 propylparaben Drugs 0.000 claims 1
- 229940083037 simethicone Drugs 0.000 claims 1
- 229940012831 stearyl alcohol Drugs 0.000 claims 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 claims 1
- 235000010374 vitamin B1 Nutrition 0.000 claims 1
- 239000011691 vitamin B1 Substances 0.000 claims 1
- 235000019164 vitamin B2 Nutrition 0.000 claims 1
- 239000011716 vitamin B2 Substances 0.000 claims 1
- 235000019158 vitamin B6 Nutrition 0.000 claims 1
- 239000011726 vitamin B6 Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 25
- 239000004480 active ingredient Substances 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 12
- 208000017520 skin disease Diseases 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 31
- 230000000694 effects Effects 0.000 description 27
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 23
- 230000003779 hair growth Effects 0.000 description 21
- 239000000047 product Substances 0.000 description 19
- 230000001737 promoting effect Effects 0.000 description 17
- 239000010677 tea tree oil Substances 0.000 description 16
- 229940111630 tea tree oil Drugs 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 14
- 229960003632 minoxidil Drugs 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 208000002874 Acne Vulgaris Diseases 0.000 description 11
- 206010000496 acne Diseases 0.000 description 11
- 210000003780 hair follicle Anatomy 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 229940113120 dipropylene glycol Drugs 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 125000005456 glyceride group Chemical group 0.000 description 8
- 208000024963 hair loss Diseases 0.000 description 8
- 230000003676 hair loss Effects 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 201000004624 Dermatitis Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000004530 micro-emulsion Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108010080146 androgen receptors Proteins 0.000 description 6
- 102000001307 androgen receptors Human genes 0.000 description 6
- 230000010494 opalescence Effects 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 5
- 125000000955 oleanolic acid group Chemical group 0.000 description 5
- 230000036556 skin irritation Effects 0.000 description 5
- 231100000475 skin irritation Toxicity 0.000 description 5
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 4
- 235000005979 Citrus limon Nutrition 0.000 description 4
- 244000131522 Citrus pyriformis Species 0.000 description 4
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 4
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000014429 Insulin-like growth factor Human genes 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229960005233 cineole Drugs 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 229960001712 testosterone propionate Drugs 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 3
- WRYLYDPHFGVWKC-SNVBAGLBSA-N 4-Terpineol Natural products CC(C)[C@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-SNVBAGLBSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- RBNWAMSGVWEHFP-UHFFFAOYSA-N cis-p-Menthan-1,8-diol Natural products CC(C)(O)C1CCC(C)(O)CC1 RBNWAMSGVWEHFP-UHFFFAOYSA-N 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000005260 corrosion Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000003660 hair regeneration Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000011587 new zealand white rabbit Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 235000002020 sage Nutrition 0.000 description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000009210 therapy by ultrasound Methods 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 2
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 2
- 101150029129 AR gene Proteins 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 240000004784 Cymbopogon citratus Species 0.000 description 2
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 2
- 244000166675 Cymbopogon nardus Species 0.000 description 2
- 235000018791 Cymbopogon nardus Nutrition 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 240000006927 Foeniculum vulgare Species 0.000 description 2
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 2
- 206010016936 Folliculitis Diseases 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- 239000005792 Geraniol Substances 0.000 description 2
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 235000007303 Thymus vulgaris Nutrition 0.000 description 2
- 240000002657 Thymus vulgaris Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 2
- 229940015301 baicalein Drugs 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- XSIFPSYPOVKYCO-UHFFFAOYSA-N butyl benzoate Chemical compound CCCCOC(=O)C1=CC=CC=C1 XSIFPSYPOVKYCO-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 2
- 229940043234 carbomer-940 Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- MMKRHZKQPFCLLS-UHFFFAOYSA-N ethyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OCC MMKRHZKQPFCLLS-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 229940045109 genistein Drugs 0.000 description 2
- 235000006539 genistein Nutrition 0.000 description 2
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 2
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 2
- 229940113087 geraniol Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003049 inorganic solvent Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229930007744 linalool Natural products 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000002539 nanocarrier Substances 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000037368 penetrate the skin Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 201000001297 telogen effluvium Diseases 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 239000001585 thymus vulgaris Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BIDDLDNGQCUOJQ-KAMYIIQDSA-N (z)-2,3-diphenylprop-2-enoic acid Chemical class C=1C=CC=CC=1/C(C(=O)O)=C/C1=CC=CC=C1 BIDDLDNGQCUOJQ-KAMYIIQDSA-N 0.000 description 1
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- BFZHCUBIASXHPK-QJSKAATBSA-N 11alpha-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)C[C@H]2O BFZHCUBIASXHPK-QJSKAATBSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- UIERETOOQGIECD-UHFFFAOYSA-N Angelic acid Natural products CC=C(C)C(O)=O UIERETOOQGIECD-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000208152 Geranium Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 240000005183 Lantana involucrata Species 0.000 description 1
- 241000830535 Ligustrum lucidum Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 241001331901 Mediterranea Species 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000795633 Olea <sea slug> Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 240000009120 Phyllanthus emblica Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 240000002924 Platycladus orientalis Species 0.000 description 1
- 235000011751 Pogostemon cablin Nutrition 0.000 description 1
- 240000002505 Pogostemon cablin Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 206010074268 Reproductive toxicity Diseases 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 235000008632 Santalum album Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241001300193 Speranskia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 241000967294 Swertia japonica Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000005396 acrylic acid ester group Chemical group 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- UIERETOOQGIECD-ARJAWSKDSA-N angelic acid Chemical compound C\C=C(\C)C(O)=O UIERETOOQGIECD-ARJAWSKDSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- UDEWPOVQBGFNGE-UHFFFAOYSA-N benzoic acid n-propyl ester Natural products CCCOC(=O)C1=CC=CC=C1 UDEWPOVQBGFNGE-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000010627 cedar oil Substances 0.000 description 1
- SVURIXNDRWRAFU-OGMFBOKVSA-N cedrol Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@@H]1[C@@](O)(C)CC2 SVURIXNDRWRAFU-OGMFBOKVSA-N 0.000 description 1
- 229940026455 cedrol Drugs 0.000 description 1
- PCROEXHGMUJCDB-UHFFFAOYSA-N cedrol Natural products CC1CCC2C(C)(C)C3CC(C)(O)CC12C3 PCROEXHGMUJCDB-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000001666 citrus aurantium l. flower Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000001224 daucus carota l. seed absolute Substances 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical group CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- SVURIXNDRWRAFU-UHFFFAOYSA-N juniperanol Natural products C1C23C(C)CCC3C(C)(C)C1C(O)(C)CC2 SVURIXNDRWRAFU-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- ZOLPMMWNCLHKPX-UHFFFAOYSA-N ligustrin Natural products CC1=CCC2C1C3OC(=C)C(=O)C3C(O)CC2=C ZOLPMMWNCLHKPX-UHFFFAOYSA-N 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- OLXYLDUSSBULGU-UHFFFAOYSA-N methyl pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1 OLXYLDUSSBULGU-UHFFFAOYSA-N 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 230000036618 natural shedding Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000010664 perilla essential oil Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- 229940107889 rogaine Drugs 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 231100000051 skin sensitiser Toxicity 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/068—Microemulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/49—Solubiliser, Solubilising system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
A high-concentration oleanolic acid nanoemulsion composition and a preparation method thereof belong to the technical fields of medicines and cosmetics. The oleanolic acid nanoemulsion composition comprises 0.01% -8% of oleanolic acid; 1% -40% of a surfactant; 1% -40% of cosurfactant; terpene-containing essential oil 0.2% -20%; 0% -2% of baicalin; 0-5% of oleuropein; a proper amount of additive; the balance being water. Adding cosurfactant and terpene-containing essential oil into a container A, and uniformly mixing and stirring; adding a surfactant, and uniformly mixing; then adding oleanolic acid and other active ingredients, and stirring until the oleanolic acid and other active ingredients are completely dissolved; adding water and additives into a container B to obtain a water phase; slowly adding the mixture of the container A into the water phase of the container B while stirring to obtain primary emulsion; high-speed shearing and emulsifying, and secondary emulsifying. Can be used in preparing cosmetics, and can be used in preparing medicines for treating skin diseases, and can be used for caring skin, hair, etc.
Description
Technical Field
The invention belongs to the technical field of medicines and cosmetics, and particularly relates to a high-concentration oleanolic acid nanoemulsion composition and a preparation method thereof.
Background
Oleanolic acid (Oleanolic acid), also known as angelic acid, is a natural pentacyclic triterpene compound that is found in a wide variety of plants, both as an episome and as a glycoside. The content is generally 0.2% -2%. The powder purified by oleanolic acid is white crystal, odorless and tasteless. Is unstable to acid and alkali. Melting point 308-310 ℃, [ alpha ]20D+73.3° (c=0.15, chloroform), insoluble in water.
Oleanolic acid has wide pharmacological effects such as antibacterial, antiinflammatory, antioxidant, antitumor, liver protecting, antidiabetic, hair growth promoting, wound healing promoting, scar formation resisting, collagen formation promoting, and antiallergic effects. At present, oleanolic acid is clinically used for the adjuvant therapy of acute and chronic hepatitis, and is safe and has no toxic or side effect. The development and utilization of oleanolic acid except liver protection are not obvious, and the clinical preparation of the oleanolic acid mainly comprises two types of tablets and capsules.
Notably, some oleanolic acid-rich herbal plants, such as the traditional Chinese medicine ligustrum lucidum, are traditionally used in china for the treatment of hair loss, promotion of hair regrowth and hair blacking; oleanolic acid has been shown to up-regulate Wnt/β -catenin signaling pathway to promote hair growth and prolong the anagen phase of hair follicles in vitro (Liu B, et al, β -Catenin is involved in oleanolic acid-dependent promotion of proliferation in human hair matrix cells in an in vitro organ culture model [ J ]. Fitterapia, 2017, 121:136-140.); oleanolic acid has been shown to promote proliferation of human hair follicle stem cells cultured in vitro (Liu Ben, chen Xianyan, yi Huan, etc. effects of oleanolic acid on proliferation of human hair follicle stem cells cultured in vitro [ J ]. J. Skin disease, chem., 2017,24 (2): 68-71.); oleanolic acid has been shown to down-regulate gene expression of 5A REDUCTASE and androgen receptor in cultured hair follicles in vitro, and up-regulate expression levels of insulin-like growth factor (IGF-1), vascular Endothelial Growth Factor (VEGF) (CaoC, liu Y, et al EFFECT OF OLEANOLIC ACID ON A-REDUCTASE ACTITY, DPCS PROLIFERATION AND GENE EXPRESSION CORRELATED WITH ANDROGENETIC ALOPECIA IN VITRO [ J ]. ACTA MEDICA MEDITERRANEA,2019,35 (4): 2159-2165.); these studies show that oleanolic acid has a broad application prospect as a product for promoting hair growth and reducing hair loss.
The oleanolic acid has good supplementing or replacing effect on the existing hair growth or hair loss treatment; the U.S. Food and Drug Administration (FDA) has approved only two drugs for the treatment of male androgenetic alopecia (AGA): topical minoxidil (minoxidil) and oral finasteride (finasteride); finasteride is an inhibitor of 5 alpha-reductase type 2, which inhibits DHT-induced hair follicle miniaturization by inhibiting the conversion of testosterone hormone (T) to Dihydrotestosterone (DHT), resulting in reduced DHT formation; finasteride is generally more effective than minoxidil for AGA patients; however, finasteride has the potential to cause male sexual side effects and cause anxiety and depression; minoxidil is a nonspecific hair growth promoting agent whose mechanism of promoting hair growth is not completely known, and minoxidil is a potassium channel opener which can promote hair growth by dilating blood vessels and allowing more blood and nutrients to enter hair follicles; common adverse effects of minoxidil are mild dermatitis, itching, redness or irritation of the scalp and hirsutism, even exacerbation of hair loss, and the "Rogaine" manufacturer indicates that minoxidil causes hair loss to be a common side effect and describes the process as "shed phase"; and the minoxidil is easy to drop to the level before the minoxidil is used after stopping the drug; minoxidil can inhibit collagen production, possibly accelerating skin aging; serious allergic reactions may occur including rash, chest distress, chest pain, dizziness, tachycardia, etc.; existing therapeutic agents are not very successful and often have undesirable side effects that deeply plague patients and dermatologists; therefore, the development of effective oleanolic acid external preparations is particularly important.
Oleanolic acid is hardly soluble in water (solubility in water: 4.61mg/L at 25 ℃) and has poor cell permeability, and oleanolic acid belongs to class VI drugs, i.e., low-solubility, low-permeability drugs, according to the biopharmaceutical classification system. And the oleanolic acid has poor solubility and low dissolution efficiency in common alcohols, fatty acids, surfactants and other fat-soluble solvents, thereby greatly limiting the application of the oleanolic acid. The choice of a suitable formulation or solvent is critical to enhance the solubility of oleanolic acid, as only the dissolved drug can penetrate the skin.
The disclosed patent on oleanolic acid preparation mentions Gao Jidun that the dispersibility of the oleanolic acid in water, but still has problems that prevent large-scale industrial production and application, such as low oleanolic acid content, and complex organic solvents or processing steps involved in the damage to human skin or health.
For example, chinese patent CN101991532B discloses a self-microemulsion composition without water, said self-microemulsion composition containing 0.4-20 mg/ml oleanolic acid, said oil phase being one or more of the following: soybean oil, isopropyl myristate, isopropyl palmitate, ethyl laurate, ethyl myristate, glyceryl oleate, glyceryl linoleate, corn oil, sesame oil, olive oil and caprylic/capric glyceride, wherein the content of the oil phase is 30-56%; oleanolic acid is dissolved by the cosurfactant/solvent and is selected from glycerol, polyethylene glycol, propylene glycol, ethylene glycol monoethyl ether, absolute ethanol, dimethylacetamide and N-methylpyrrolidone; in example 22, in which the content of oleanolic acid is up to 20mg/mL, the total surfactant content used is up to 66%, the content of N-methylpyrrolidone (NMP) which is a main solvent is 25%, but N-methylpyrrolidone (NMP) has the harm of irritation, reproductive toxicity and the like, and dimethylacetamide which is a relatively efficient solvent has obvious irritation and toxicity to human bodies and skin, has teratogenicity and is not suitable for long-term use in high concentration.
Chinese patent application No. CN03125480.2 discloses an emulsion for injection of oleanolic acid and a preparation method thereof, comprising: 0.08-2 g/L oleanolic acid, 5-30 g/L injection phospholipid, 50-200 g/L injection soybean oil, 22-25 g/L glycerol and the balance of injection water. The preparation method comprises mixing oleanolic acid and soybean oil to obtain oil phase; mixing and stirring phospholipid, glycerol and water for injection to obtain water phase; adding the oil phase into the water phase under stirring, adjusting the pH to 6.5-7.0, and adding water for injection to obtain crude milk; homogenizing the crude milk with a high pressure homogenizer to obtain emulsion. The emulsion is prepared by adopting the traditional method of mixing and homogenizing oil phase and water phase, and the particle size of the prepared emulsion is larger, about 1 mu m; and the oleanolic acid content is low, the dissolving process is time-consuming, and the process is complex.
Chinese patent CN2011800558173a relates to a soluble cosmetic composition, which uses nanoliposome to embed oleanolic acid to enhance percutaneous absorption of oleanolic acid to promote synthesis of collagen, thereby improving anti-wrinkle effect; the preparation method comprises mixing hydrogenated lecithin, PEG-60 hydrogenated castor oil and other surfactants with polyalcohol, heating to 80deg.C for dissolving, and adding 0.05% oleanolic acid and other additives for mixing; cooling the obtained mixture to 65 ℃, and then adding ethanol into the mixture; uniformly mixing the components of the aqueous portion and heating to 65 ℃ and mixing with the mixture obtained before; the preparation method has the main defects of complex preparation process, multiple heating and cooling requirements, high cost and poor liposome stability; in addition, regardless of how the proportions of surfactant, polyol and water are adjusted, the solvent is limited in its dissolving power, and generally contains only 0.05% oleanolic acid, at a relatively low concentration.
In order to solve the problem of insufficient application of oleanolic acid, the invention uses a pharmaceutical carrier nanoemulsion (nanoemulsion). Nanoemulsions are defined as emulsion systems consisting of an oil phase with a surfactant and water, having an isotropic, transparent (or translucent) appearance. Droplet size is defined as less than 200nm. However, if the emulsion has a low surfactant content and is kinetically stable, dimensions less than 500nm may be accepted as nanoemulsions. These nanocarriers have transparency, low viscosity, thermodynamic stability, ease of preparation, and high surface area making them an effective transdermal and topical drug delivery system; moreover, they have several substantial advantages over other nanocarriers (e.g., microemulsions, liposomes), including low use of surfactants, low skin irritation, high penetration capacity, and high drug loading, and can be used for topical treatment. The nanoemulsion can be used as an initial material for preparing nanocapsules and nanospheres, and can also be prepared into different local formulations, such as foams, gels, creams, liquids and sprays. Although the microemulsion and nanoemulsion are similar in size, their methods of preparation are different. Both of them require energy input, but nanoemulsions mostly use mechanical shear, whereas microemulsions use spontaneous emulsification methods. Microemulsions also require high surfactant concentrations compared to nanoemulsions.
The nanoemulsion gel is formed by adding water-soluble polymer materials such as carbomer, poloxamer, gelatin, cellulose and the like into nanoemulsion to form transparent and stable reticular colloid. The nanoemulsion gel can increase the viscosity of nanoemulsion, improve the adhesiveness and spreadability of nanoemulsion and skin, and the diffusion of the medicine in the gel is blocked due to the increase of the viscosity of the system, the effective diffusion coefficient is reduced, and the volatilization of components is reduced, so that the medicine can maintain longer action time. Is favorable for the full absorption of the medicine, thereby improving the bioavailability of the medicine, being convenient and sanitary to use, being not easy to pollute clothes and having better compliance of patients.
Disclosure of Invention
The invention aims to provide a high-concentration oleanolic acid nanoemulsion composition and a preparation method thereof aiming at the defects existing in the prior art.
Another object of the present invention is to provide the use of the oleanolic acid nanoemulsion composition.
The oleanolic acid nanoemulsion composition comprises the following components in percentage by weight:
0.01 to 8 percent of oleanolic acid, 1 to 40 percent of surfactant, 1 to 40 percent of cosurfactant, 0.2 to 20 percent of terpene-containing essential oil, 0 to 2 percent of baicalin, 0 to 5 percent of oleuropein, a proper amount of additive and the balance of water.
Preferably, the oleanolic acid nanoemulsion composition comprises the following components in percentage by weight:
0.5 to 2 percent of oleanolic acid, 10 to 30 percent of surfactant, 10 to 25 percent of cosurfactant, 1 to 10 percent of terpene-containing essential oil, 0.1 to 1 percent of baicalin, 0.5 to 2 percent of oleuropein, a proper amount of additive and the balance of water.
The oleanolic acid can be pure product or plant extract containing oleanolic acid; the plant extract contains at least 2% oleanolic acid, and can be selected from one of fructus Ligustri Lucidi extract, swertia Japonica Makino extract, herba Swertiae Mileensis extract, fructus Canarii albi extract, etc.
The surfactant is preferably a nonionic surfactant; the surfactant may have an HLB value of from 8 to 18, preferably an HLB value of from 10 to 15; the surfactant may be at least one selected from PEG-6 caprylic/capric glyceride, PEG-8 caprylic/capric glyceride, tween 80, tween 20, polyoxyethylene 40 hydrogenated castor oil, polyoxyethylene castor oil, glyceryl monostearate, span 80, glyceryl monostearate, hydrogenated lecithin, steareth, polyethylene glycol stearate, and polyglyceryl fatty acid ester.
The cosurfactant can be at least one selected from diethylene glycol monoethyl ether, dipropylene glycol, 1, 3-butanediol, ethanol, 1, 2-pentanediol, 1, 2-hexanediol, propylene glycol, glycerol, polyethylene glycol and the like; diethylene glycol monoethyl ether is preferred.
Wherein the terpene containing essential oil contains a terpene structurally belonging to the group of mono-, sesqui-, di-or triterpenes, at least 1% of the terpene, more preferably at least 10% of the terpene, by weight of the terpene containing essential oil. Terpene containing essential oils include, but are not limited to, cedar essential oils, eucalyptus essential oils, peppermint essential oils, tea tree essential oils, lavender essential oils, sage essential oils, clove bud essential oils, cedar essential oils, geranium essential oils, lemon grass essential oils, sage essential oils, turmeric essential oils, wintergreen essential oils, rosemary essential oils, fennel essential oils, chamomile essential oils, guava essential oils, fennel essential oils, basil essential oils, camphor essential oils, kanan, citronella essential oils, cinnamon essential oils, ginger essential oils, perilla essential oils, rose essential oils, patchouli essential oils, sandalwood essential oils, bay essential oils, carrot seed essential oils, bergamot essential oils, grapefruit essential oils, lemon essential oils, citrus essential oils, orange essential oils, oregano essential oils, sweet orange essential oils, thyme essential oils, and other suitable essential oils.
The terpene-containing essential oil is preferably at least one of eucalyptus oil, tea tree essential oil, cedar essential oil, peppermint essential oil, lavender essential oil, rosemary essential oil, etc.; the terpene-containing essential oil comprises, by weight, 0.2% -10% of eucalyptus oil, 0.2% -10% of tea tree essential oil, 0.3% -5% of cedar essential oil, 0.8% -3.2% of peppermint essential oil, 0.6% -2.4% of lavender essential oil and 0.5% -3.2% of rosemary essential oil, preferably: 0.3 to 12 percent of eucalyptus oil, 0.3 to 10 percent of tea tree essential oil, 0.3 to 5 percent of cedar essential oil, 0.8 to 3.2 percent of peppermint essential oil, 0.6 to 2.4 percent of lavender essential oil and 0.5 to 3.2 percent of rosemary essential oil; more preferably: 0.5 to 2 percent of eucalyptus oil, 0.5 to 2 percent of tea tree essential oil, 0.3 to 1 percent of cedar essential oil, 0.8 to 2.0 percent of peppermint essential oil, 0.5 to 1.2 percent of lavender essential oil and 0.5 to 1.6 percent of rosemary essential oil.
The additives may include thickeners, humectants, pH adjusters, preservatives, antioxidants, conditioning agents, chelating agents, ultraviolet absorbers, nutrients, or other suitable additives. Such other suitable additives include, but are not limited to, at least one of an emollient, an anti-androgenic agent, a hair tonic, and the like.
The thickener is selected from carbomer, hydroxyethyl cellulose, sodium carboxymethylcellulose, sodium alginate, polycarbophil, poloxamer, xanthan gum, aloe vera gel, guar gum, polyquaternary ammonium salt Q-10, acrylic acid, and acrylic acid ester; carbomers are preferred; the usage amount of the thickener is preferably 0.1% -5% of the total weight of the nanoemulsion;
the humectant is at least one selected from astragalus polysaccharide, sodium hyaluronate, dipotassium glycyrrhizinate, glycerol, polyethylene glycol, sorbitol, maltitol, aloe vera gel, sodium lactate, squalane, etc.; preferably astragalus polysaccharides and sodium hyaluronate; the usage amount of the humectant is preferably 0.5-5% of the total weight of the nanoemulsion.
The pH adjustor can be selected from the group consisting of citric acid, malic acid, lactic acid, phosphoric acid, triethanolamine, and combinations thereof, preferably triethanolamine; the pH regulator is preferably used in an amount of 0.1-1% of the total weight of the nanoemulsion.
The preservative can be selected from p-hydroxyacetophenone, phenoxyethanol, benzoic acid, octanoyl hydroxamic acid, octanoyl glycol, methyl benzoate, ethyl benzoate, propyl benzoate, butyl benzoate, dimethylaminoethanol, benzalkonium chloride, benzalkonium bromide and the like, and the use amount of the preservative is preferably 0.1-0.6% of the total weight of the nanoemulsion.
The antioxidant is one or more selected from sodium bisulphite, vitamin E, vitamin C, lauryl gallate, propyl gallate, phenethyl caffeate, arbutin, ferulic acid, magnesium ascorbyl phosphate, sodium ascorbyl phosphate and ascorbyl ethyl ether.
The conditioner is one or more of allantoin, dipotassium glycyrrhizinate, tocopheryl acetate, baicalein, olive leaf extract, baical skullcap root extract, lavender extract, chamomile extract, witch hazel extract, purslane extract, gentian root extract and rosemary extract.
The chelating agent is selected from EDTA, EDTA-2Na or EDTA-4Na.
The ultraviolet absorbent is at least one selected from baicalin derivatives, quercetin derivatives, p-aminobenzoic acid derivatives, salicylic acid derivatives, benzophenone derivatives, diphenylacrylic acid esters, cinnamic acid derivatives, etc.
The nutritional agent is at least one selected from lysine, cystine, arginine, collagen, biotin, chondroitin sulfate, keratan sulfate, heparin sulfate, polypeptide, vitamins A, B1, B2, B6, E, C, vitamin C derivatives and the like.
The emollient is selected from cetostearyl alcohol, lanolin, isopropyl isostearate, vaseline, liquid paraffin, polydimethylsiloxane, dimethiconol, dimethicone, shea butter, cetyl isooctanoate, natural squalane, octyl methoxycinnamate.
The antiandrogen agent can be at least one selected from finasteride, dutasteride, irinotecan, bicalutamide, carthamin, equol, soybean isoflavone, ligustrin, hinokitiol, saw palmetto extract, kuh-seng extract, red sage extract, lavender extract, genistein, turmeric extract, phyllanthus emblica extract, nettle extract, speranskia herb extract, ganoderma lucidum extract, dittany bark extract, azelaic acid, quercetin, myricetin, magnolol, luteolin, kaempferol, rutin, tea polyphenol, curcumin, emodin, baicalein, tea tree extract, kudzuvine root extract, genistein, baicalin, cimetidine, cyproterone, hexane estrol, 11-alpha-hydroxy progesterone, norgestrel, levonorethindrone, norethindrone, and the like.
The pilatory is selected from one or more of Polygoni Multiflori radix extract, fructus Ligustri Lucidi extract, carthami flos extract, folium Platycladi extract, herba Rosmarini officinalis extract, ginseng radix extract, notoginseng radix extract, green tea extract, herba Centellae extract, herba Swertiae Mileensis extract, semen Pisi Sativi extract, ginsenoside, radix Angelicae sinensis extract, folium Oleae Europaeae extract, radix astragali extract, rhizoma Ligustici Chuanxiong extract, rhizoma Zingiberis recens extract, semen Sesami Niger extract, semen Cuscutae extract, ecliptae herba extract, folium Mori extract, epigallocatechin gallate (EGCG), cypress wood alcohol, stilbene glucoside, adenosine, caffeine, and minoxidil.
The water may be selected from distilled water, purified water and/or deionized water, preferably distilled water.
The additive of the oleanolic acid nanoemulsion composition of the present invention is usually such that a fat-soluble component is dissolved in the oil phase of the emulsifying system and a hydrophilic component is dissolved in the water phase component of the emulsifying system.
When the dosage form of the present invention is an ointment, paste, cream or gel, as a carrier component, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talc, zinc oxide or mixtures thereof can be used.
When the dosage form of the present invention is a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or mixtures thereof may be used as carrier components, especially when the dosage form is a spray, propellants such as chlorofluorocarbons, propane/butane or dimethyl ether and the like may be further included.
When the dosage form of the present invention is an emulsion, a liquid diluent such as water, ethanol or propylene glycol may be used as the carrier component.
The preparation method of the oleanolic acid nanoemulsion composition comprises the following steps:
1) Adding a formula amount of cosurfactant and terpene-containing essential oil into a container A, and uniformly mixing and stirring; adding surfactant with formula amount, and mixing; then adding oleanolic acid with formula amount, and further adding other fat-soluble components (such as baicalin) and stirring until completely dissolving;
2) Adding water with a formula amount into a container B, and further adding a proper amount of additives to obtain a water phase;
3) Slowly adding the mixture of the container A into the water phase of the container B while stirring to obtain primary emulsion;
4) And 3) performing high-speed shearing emulsification on the primary emulsion prepared in the step 3), and performing secondary emulsification by using a high-pressure homogenizing and emulsifying device, so that the oleanolic acid nanoemulsion composition is obtained after full emulsification.
In the step 1), the mass ratio of the cosurfactant to the terpene-containing essential oil is 4:1-1:1; the dissolution can be stirred at the normal temperature of 25-40 ℃ until the dissolution is completed, or the mixture is heated and stirred at the water bath condition of 40-80 ℃ until the dissolution is completed;
in the step 4), the high-pressure homogenizing and emulsifying device is used for secondary emulsification, the homogenizing speed is 4000-10000 rpm, the homogenizing time is 3-10 min, the high-pressure homogenizing pressure is 800-1000 bar, and the homogenizing is carried out for 3-5 times; the average particle size of the liquid drops in the prepared oleanolic acid nanoemulsion composition can be 10-200 nm, and is preferably less than 100nm; the secondary emulsification can also adopt micro-jet emulsification or ultrasonic emulsification.
The composition of the present invention is used as a nanoemulsion, and the average particle diameter of the droplets is preferably 10 nm to 200 nm. The emulsification process can be selected from the following steps: self-emulsifying, ultrasonic emulsifying, or microfluidizing; if self-emulsifying is used, stirring and uniformly mixing the primary emulsion to obtain nano emulsion; if ultrasonic emulsification is used, the primary emulsion is subjected to ultrasonic treatment at normal temperature, the power is 0.1-75 KW, the frequency is 20 KHz-500 MHz, the time interval is 3s when each ultrasonic wave is 3-5 s, and the whole ultrasonic treatment time is 15-300 s; if the microjet is emulsified, the primary emulsion is added into a microjet high-pressure homogenizer, and is treated for three times by increasing the pressure, the pressure is 1000bar, 1200bar and 1400bar in sequence, and then the obtained solution is filtered by an ultra-micro filter membrane with the aperture of 100 nm.
The oleanolic acid nanoemulsion composition can be applied to preparation of cosmetics. The cosmetics include, but are not limited to, hair growth lotion, hair care essence, skin care gel, anti-aging formulation, shampoo, skin foundation, essence lotion, make-up lotion, toner, acne lotion, emulsion, microemulsion, shampoo, gel, perfume, hair wax, hair conditioner, hair mask, mascara, hair oil, massage oil, hair conditioner, hair blacker, hair dye, hair gel, hair mousse, and the like.
The oleanolic acid nanoemulsion composition is used in a medicament or a cosmetic for improving or preventing alopecia, hair rarefaction, white hair, acne, seborrheic dermatitis, folliculitis, skin aging or other unhealthy skin conditions. The alopecia includes androgenetic alopecia, telogen effluvium, alopecia areata or other types of alopecia.
The oleanolic acid nanoemulsion composition can be used for skin, hair, facial skin care and the like.
The oleanolic acid nanoemulsion composition can be added with an excipient to be used as a dosage form for skin or hair care, and the oleanolic acid nanoemulsion composition is used alone as a product or is mixed with other cosmetic or medicine raw materials to prepare nanoemulsion gel, ointment, cream, emulsion, spray, lotion, liniment, patch or coating dosage form.
In the embodiment of the invention, oleanolic acid and terpene-containing essential oil are taken as active ingredients, and other functional ingredients such as baicalin can be added. Baicalin has effects of resisting skin allergy, relieving inflammation, inhibiting bacteria, preventing corrosion, and resisting oxidation, and can be used for preventing and treating skin allergy. Baicalin can absorb ultraviolet rays, scavenge oxygen free radicals, inhibit melanin generation, antagonize Androgen Receptor (AR) and reduce AR gene expression, and can reduce alopecia and acne. Baicalin is extremely insoluble in various inorganic and organic solvents, and is poor in water solubility and fat solubility, so that the nanoemulsion system can achieve better dissolution and improve bioavailability and biological efficacy.
Examples of nanoemulsions according to the invention as cosmetic and/or pharmaceutical compositions also include oleuropein (oleuropein). Oleuropein is a glycosylated terpenoid, is a main effective component of olive leaf extract, has powerful antibacterial and antiviral properties, and has extremely strong antioxidant capacity. It has been demonstrated that topical application of oleuropein promotes collagen growth and increases VEGF, IGF-1, KGF, HGF expression, and these growth factors are closely related to skin healing and hair growth, thus also promoting hair growth, accelerating wound healing, soothing and calming the skin.
Embodiments of the present invention as cosmetic and/or pharmaceutical compositions may also comprise astragalus polysaccharides. The astragalus polysaccharide has the functions of antioxidation and aging resistance, and has good hygroscopicity, thereby playing a role in moisturizing skin; polysaccharides also have a thickening effect, so that astragalus polysaccharides can be used as a thickening agent; in addition, the astragalus polysaccharide has the effect of promoting hair regeneration and has good synergistic effect with oleanolic acid.
Compared with the prior art, the invention has the outstanding advantages and technical effects that:
1. the particle size of the liquid drops in the oleanolic acid nanoemulsion is nanoscale, the particle size is less than 200nm, the liquid drops are spherical and distributed uniformly, and the defects of larger particle size and poor thermodynamic stability of the traditional emulsion are overcome: the dispersibility of the oleanolic acid in water is obviously improved, the solubility is improved by more than 10000 times, and the bioavailability of the oleanolic acid is improved. The oleanolic acid nanoemulsion composition can greatly improve the solubility and the dissolution rate of oleanolic acid, can also improve the drug loading rate after being prepared into a dosage form, improves the treatment or improvement effect, and is beneficial to the application of oleanolic acid in cosmetics and external pharmaceutical preparations.
2. The positive characteristics (namely physiological activity) of the oleanolic acid are combined with terpene-containing essential oil with good transdermal absorption capacity and nutrition or healing effect, and the combination of the oleanolic acid and the terpene-containing essential oil plays an excellent synergistic effect; the two are combined by intermolecular force, the terpene-containing essential oil enhances the dissolution and percutaneous absorption of oleanolic acid, the oleanolic acid reduces volatilization of the essential oil, and sensitization of the essential oil to individual skin sensitizers is reduced or prevented.
3. The oleanolic acid nanoemulsion is an isotropic, good-fluidity, clear, transparent or semitransparent dispersion system with slightly opalescence formed by oleanolic acid under the combined action of the essential oil, the surfactant and the cosurfactant, can be kept clear after being diluted by water, has good organoleptic properties, can reduce viscosity and greasy feel by taking the essential oil as an oil phase, has natural plant fragrance, and has excellent practical use comfort.
4. Improves the anti-corrosion capability of the product, and reduces or even does not add anti-corrosion additives. The essential oil used by the nanoemulsion has an antibacterial and antiseptic effect, and the oleanolic acid also has a strong antibacterial effect, so that the product deterioration can be prevented without adding a chemical preservative, the skin irritation is reduced, and the safety is improved.
5. Oleanolic acid is required to penetrate the skin to exert its effect, and must be able to penetrate the stratum corneum barrier to reach the corresponding sites of action and maintain a certain effect time at these sites. The nanoemulsion has small particle size, and is beneficial to transdermal absorption and efficacy of the efficacy components; one or more natural plant essential oils with penetration promoting effect are used, chemical penetration promoting agents are not needed to be added, the percutaneous absorption capacity of oleanolic acid and other active ingredients in the composition is improved, and the safety is better; the nanoemulsion contains water, so that the skin has better hydration property and is more favorable for absorption.
6. The preparation process of the product is simple and is beneficial to environmental protection. The traditional emulsion cosmetics or external medicinal preparations have complex oil phase and water phase components, more additives, complicated process flow and longer production period because of the need of using various raw materials, or use toxic and harmful solvents for improving the dissolution amount of oleanolic acid; the preparation process of the invention can be carried out under the room temperature condition, has stable compatibility with active ingredients, can contain essential oil and other additives without denaturing the essential oil and other additives, has simple preparation ingredients, low cost and simple preparation process, is easy for industrial production and reduces environmental pollution.
Drawings
FIG. 1 is a product appearance diagram of oleanolic acid nanoemulsion compositions prepared in examples 1-6.
Fig. 2 is a graph showing the comparison of the groups after experimental example 1 of the effect of oleanolic acid nanoemulsion on androgen alopecia model mice.
Wherein A is a blank group; b is a model group; c is minoxidil group; d is 1% oleanolic acid group (group 4); e is oleanolic acid + oleuropein + baicalin group (group 5).
Detailed Description
The invention will be further illustrated by the following examples in conjunction with the accompanying drawings. The exemplary compositions are merely illustrative and do not limit the scope of the invention. The proportions of the examples and other parts of the specification are by weight unless otherwise indicated. The following formulations are directed to nanoemulsion, gel embodiments; however, similar techniques may also be used in other types of cosmetic or laundry products, including but not limited to shampoos, creams, sprays, conditioners, and styling products.
The invention relates to a nanoemulsion carrier of oleanolic acid. The terpenoid refers to derivatives with a general formula of (C5H 8) n and oxygen content and different saturation degrees, the derivatives are widely existing in the natural world, monoterpenes and sesquiterpenes are widely existing in plant essential oil, and oleanolic acid is a pentacyclic triterpene compound and belongs to terpenes. The solubility of the essential oil in alignment with oleanolic acid is of interest to the inventors based on the principle of similar miscibility; according to the assay of the present invention, many terpene containing plant essential oils have surprising solubilization of oleanolic acid, such as eucalyptus oil, tea tree essential oil, cedar essential oil, lavender essential oil, rosemary essential oil, peppermint essential oil, lemon essential oil, carrot seed oil, and the like; in addition, some essential oils contain a large amount of liquid terpene monomers, such as Eucalyptol (Eucalyptol) of eucalyptus oil and rosemary essential oil, terpin-4-ol (terpin-4-ol) of tea tree oil, linalool (linalol) of lavender essential oil, geraniol (Geraniol) of rose essential oil and the like, which have excellent oleanolic acid solubility.
The applicant has found that nanoemulsions containing terpene containing essential oils as the oil phase are suitable matrices for oleanolic acid. Thus, the positive properties of oleanolic acid are combined with nanoemulsions comprising terpene containing essential oils. In particular, nanoemulsions can be produced with high oleanolic acid loading, which combine the positive properties of oleanolic acid (i.e. physiological activity) with terpene containing essential oil having good transdermal absorption capacity and nutritional or healing effects, if any. This makes the nanoemulsion formulation particularly suitable for cosmetic or dermatological preparations of triterpenes.
The preparation method is characterized in that a mixture of a cosurfactant and terpene-containing essential oil in a mass ratio of 4:1-1:1 is used for solubilizing oleanolic acid: not only can prevent coagulation from occurring in the middle of dissolution, but also can greatly increase the concentration of oleanolic acid in the preparation.
In embodiments of the present invention, novel utilities and/or advantages may be provided when the essential oils are both carriers and solvents and active ingredients; the invention seals the essential oil in the nano system as the oil phase, can improve the solubility of oleanolic acid, and plays a synergistic effect with the active ingredients in application.
Essential oils in embodiments of the present invention have a number of valuable properties that can be used as combination therapies; plant essential oils are useful in dermatological patients, and they generally have antibacterial, antifungal, anti-inflammatory, astringent and regenerating properties; can be used for aromatherapy for treating dermatoses such as dandruff, psoriasis, eczema, acne, and seborrheic dermatitis; can have very beneficial synergistic effects as active ingredients and/or enhancers in the intended application, in particular as androgen antagonists and hair growth promoters; essential oils such as eucalyptus oil, peppermint oil, tea tree oil and the like have been widely studied and reported as penetration enhancers to increase transdermal drug delivery; in addition, the encapsulation of the nano system can provide the controlled release of bioactive components such as oleanolic acid and the like, and provide better stability of essential oil and other volatile compounds, and improve the bioavailability and biological efficacy of the preparation.
And from a toxicological point of view, essential oils are considered safer and less irritating than other chemical permeation enhancers; essential oils or fixed oils extracted from aromatic plants are widely used in foods, cosmetics and pharmaceuticals, many of which are listed in the us FDA (us food and drug administration) list of Generally Recognized As Safe (GRAS), i.e. "acknowledged safety compounds", essential oils, oleoresins (without solvents) and natural extracts (including distillates) are generally considered safe for their intended use (foods, cosmetics), such as menthol, peppermint, rosemary, sage, orange flowers, lemon GRASs, thyme, orange leaves, citronella, ylang, etc., and are also suitable for long-term use without risk.
Eucalyptus oil, also called as UGANLI essential oil, has antibacterial, antioxidant, antiinflammatory, permeation promoting, insecticidal, mosquito repellent, antipruritic, and antiseptic effects, is a good raw material for medicine and perfume, and is widely used in food processing and cosmetics. Eucalyptus oil is also used to improve blood circulation of the scalp, thereby promoting hair growth.
The tea tree essential oil has powerful cleaning, antibacterial, anti-inflammatory and antiseptic properties, and is suitable for oily and acne skin, and can be used for treating suppurative wound, burn, sunburn, psoriasis, dandruff, etc. In addition, tea tree essential oil has weak estrogen-like activity, and in vitro studies prove that the expression of androgen receptor can be reduced, so that androgenetic alopecia can be reduced.
It is well known that peppermint essential oil can produce a cooling sensation and promote blood circulation, helps reduce skin inflammation and itching, and has been demonstrated to promote hair growth.
Cedrol, the main ingredient of cedar essential oil, is also the main active ingredient of cacumen Platycladi, and has vasodilating effect on blood vessel, and can stimulate hair follicle to generate new hair growth, and inhibit natural shedding process. In addition, the cedar essential oil has strong antifungal and antibacterial properties, and the addition of the cedar essential oil in the treatment of acne helps to relieve and reduce intractable acne outbreaks.
Lavender essential oils have been shown to have weak estrogenic activity and very strong anti-inflammatory properties, and can play a key role in helping users relieve itching, swelling of the skin, and increase the rate of wound healing, thereby providing a good environment for skin repair and hair growth.
The rosemary essential oil has strong astringing effect, improves greasy desquamation skin, promotes blood circulation, and can stimulate hair regeneration.
In some embodiments, the composition may contain other additives such as thickeners, humectants, pH adjusting agents, stabilizers, preservatives, antioxidants, conditioning agents, emollients, colorants, skin protectants, skin and hair nutrients such as collagen, elastin, keratin, and other suitable additives.
In some embodiments, the composition comprises a humectant selected from one or more of astragalus polysaccharides, sodium hyaluronate, dipotassium glycyrrhizinate, glycerin, aloe vera gel, more preferably astragalus polysaccharides and sodium hyaluronate;
in some embodiments, the composition may further comprise a thickening agent, such as a naturally derived thickening agent, e.g., carbomer, hydroxyethyl cellulose, sodium carboxymethyl cellulose, sodium alginate, poloxamer 407, xanthan gum, guar gum, more preferably carbomer.
In some embodiments, the composition may further comprise a pH adjuster, which may be selected from the group consisting of citric acid, malic acid, lactic acid, phosphoric acid, triethanolamine, and combinations thereof, preferably triethanolamine.
In some embodiments, the composition may not need to be added with a preservative, for example, the essential oil and 1, 3-butanediol, ethanol, 1, 2-pentanediol, 1, 2-hexanediol all have antiseptic and bacteriostatic effects; in some embodiments, small amounts of preservatives including p-hydroxyacetophenone, phenoxyethanol may be optionally used.
The compositions of the present invention are hydrophilic in nature. The water may be distilled, purified and/or deionized, preferably distilled water. In some embodiments, the composition comprises about 1% to 80% water by weight.
The average particle size of the liquid drops in the oleanolic acid nanoemulsion composition is 10-200 nm, and the particle size of the nanoemulsion is preferably smaller than 100nm. The application process can be one or more of high-pressure homogenization in high-energy emulsification, micro-jet or ultrasonic, and high-pressure homogenization is preferred.
The obtained nanoemulsion can be used alone, or can be further added with other excipients to prepare nanoemulsion gel, cream, emulsion, spray, transdermal patch, ointment and the like.
According to the preparation method provided by the invention, terpene-containing essential oils such as eucalyptus oil, tea tree oil and cedar oil have higher solubility in oleanolic acid, however, when the dissolution amount of oleanolic acid in the essential oils exceeds 40mg/mL, white colloidal coagulation is easy to form, and further dissolution is seriously hindered.
The preparation method is characterized in that a mixture of a cosurfactant and terpene-containing essential oil in a mass ratio of 4:1-1:1 is used for solubilizing oleanolic acid: not only can prevent coagulation in the middle of dissolution, but also can greatly increase the concentration of oleanolic acid in the preparation;
in embodiments of the present invention, novel utilities and/or advantages may be provided when the essential oils are both carriers and solvents and active ingredients; the invention seals the essential oil in the nano system as a lipophilic phase, can improve the solubility of oleanolic acid, and plays a synergistic effect with active ingredients in application.
The oleanolic acid nanoemulsion composition of the present invention may further comprise other hydrophilic or fat-soluble active ingredients, thereby enabling cosmetics or external preparations to have a stronger activity. In general, the fat-soluble active ingredient is dissolved in the oil phase of the emulsifying system and the hydrophilic ingredient is dissolved in the water phase of the emulsifying system. The addition of active ingredients such as baicalin with antiandrogenic action, other active ingredients such as oleuropein, astragalus polysaccharides should be noted. The formula of the nanoemulsion composition is embodied in dosage forms such as nanoemulsion, essence, gel or shampoo, and therefore, the nanoemulsion also comprises auxiliary components such as thickening agents, moisturizing agents, preservatives and the like.
In the embodiment of the invention, the oleanolic acid and the terpene-containing essential oil are taken as active ingredients, and other active ingredients and/or reinforcing agents such as baicalin can be added. Other active ingredients and/or enhancers such as baicalin may also be added to embodiments of the present invention. Baicalin is known to have the effects of resisting skin allergy, resisting inflammation, inhibiting bacteria, preserving and resisting oxidation, and can be used for preventing and treating skin allergy. Baicalin can absorb ultraviolet rays, scavenge oxygen free radicals, inhibit melanin generation, antagonize Androgen Receptor (AR) and reduce AR gene expression, and can reduce alopecia and acne. Baicalin is extremely insoluble in various inorganic and organic solvents, and is poor in water solubility and fat solubility, so that the nanoemulsion system can achieve better dissolution and improve bioavailability and biological efficacy.
Examples of nanoemulsions according to the invention as cosmetic and/or pharmaceutical compositions also include oleuropein (oleuropein). Oleuropein is a glycosylated terpenoid, is a main effective component of olive leaf extract, has powerful antibacterial and antiviral properties, and has extremely strong antioxidant capacity. It has been demonstrated that topical application of oleuropein promotes collagen growth and increases VEGF, IGF-1, KGF, HGF expression, and these growth factors are closely related to skin healing and hair growth, thus also promoting hair growth, accelerating wound healing, soothing and calming the skin.
Embodiments of the present invention as cosmetic and/or pharmaceutical compositions may also comprise astragalus polysaccharides. The astragalus polysaccharide has the functions of antioxidation and aging resistance, and has good hygroscopicity, thereby playing a role in moisturizing skin; polysaccharides also have a thickening effect, so that astragalus polysaccharides can be used as a thickening agent; in addition, the astragalus polysaccharide has the effect of promoting hair regeneration and has good synergistic effect with oleanolic acid. Other plant extracts with hair growth promoting and antiandrogenic effects, such as ginsenoside, ginseng radix extract, polygoni Multiflori radix extract, herba Rosmarini officinalis extract, carthami flos extract, platycladus orientalis extract, scutellariae radix extract, etc. can be used in the preparation of the present invention.
Because the quality standards of the same functional components and raw materials are not identical at present, and particularly the content and purity of the essential oil components are different, the solubility of the active components can be influenced, and therefore, great attention is paid to the quality and source of the raw materials when the product is prepared. In the embodiment of the invention, the content of eucalyptol in eucalyptus oil is more than or equal to 80%, the content of terpin-4-ol in tea tree oil is more than or equal to 42%, the content of linalool in lavender essential oil is more than or equal to 31%, the content of eucalyptol in rosemary essential oil is more than or equal to 26%, the content of cedar essential oil is more than or equal to 11%, the content of peppermint essential oil is peppermint essential oil, and the content of menthol is more than or equal to 36%; the purity of diethylene glycol monoethyl ether is more than or equal to 99.5%, and is cosmetic grade or medical grade, preferably Transcutol CG or Transcutol HP.
Specific examples are given below.
Example 1:
the 1% oleanolic acid nanoemulsion comprises the following raw material components in percentage by weight as shown in table 1:
TABLE 1
Component (A) | Weight percent (%) |
Oleanolic acid | 1 |
Eucalyptus oil | 1 |
Tea tree oil | 2 |
Rosemary essential oil | 1.2 |
Peppermint essential oil | 2 |
Lavender essential oil | 0.8 |
Diethylene glycol monoethyl ether (Transcutol) | 16 |
Dipropylene glycol | 5 |
Tween 20 | 25.00 |
Polyoxyethylene 35 castor oil | 8 |
Distilled water | 37.8 |
The preparation method comprises the following steps:
(1) and weighing eucalyptus oil, tea tree oil, rosemary essential oil, peppermint essential oil and lavender essential oil according to the formula amount, and uniformly mixing the eucalyptus oil, the tea tree oil, the rosemary essential oil, the peppermint essential oil and the lavender essential oil with diethylene glycol monoethyl ether and dipropylene glycol in a container A.
(2) Weighing Tween 20 and polyoxyethylene 35 castor oil, adding into the mixture of container A, mixing, adding oleanolic acid, and stirring to dissolve completely.
(3) Distilled water was added to vessel B followed by mixing well.
(4) Adding the mixture of the container A into the container B under stirring to obtain primary emulsion, and then emulsifying for the second time by using a high-pressure homogenizing emulsifying device, wherein the homogenizing speed is 5000rpm, the homogenizing time is 5min, the high-pressure homogenizing pressure is 800bar, and homogenizing is carried out for 3-5 times.
(5) And (3) closing the high-pressure homogenizer, and taking a small amount of finished products for observation, wherein the appearance is transparent or semitransparent, the fluidity and the dispersibility are good, and the oleanolic acid nanoemulsion is obtained when the oleanolic acid nanoemulsion has obvious visible opalescence.
Example 2:
the 1% oleanolic acid nanoemulsion comprises the following raw material components in percentage by weight as shown in table 2:
TABLE 2
Component (A) | Weight percent (%) |
Oleanolic acid | 1 |
Eucalyptus oil | 2 |
Tea tree oil | 2 |
Lavender essential oil | 1.2 |
Peppermint essential oil | 1.8 |
Dipropylene glycol | 5 |
Ethanol | 3 |
1, 2-hexanediol | 8 |
PEG-6 caprylic/capric glyceride | 16 |
Polyoxyethylene 35 castor oil | 12 |
Biotin | 0.5 |
Dipotassium glycyrrhizinate | 0.5 |
Distilled water | 47 |
The preparation method comprises the following steps:
(1) the eucalyptus oil, tea tree oil, peppermint essential oil, lavender essential oil, 1, 2-hexanediol, ethanol, dipropylene glycol, PEG-6 caprylic/capric glyceride and polyoxyethylene 35 castor oil with the formula amounts are weighed and evenly mixed in a container A.
(2) The oleanolic acid with the formula amount is weighed and added into the mixture of the container A, and the mixture is placed in a water bath with the temperature of 80 ℃ for heating and stirring until the oleanolic acid is completely dissolved.
(3) Distilled water is added into the container B, and biotin and dipotassium glycyrrhizinate are added and stirred until dissolved.
(4) Adding the mixture of the container A into the container B under stirring to obtain primary emulsion, and then emulsifying for the second time by using a high-pressure homogenizing emulsifying device, wherein the homogenizing speed is 4000rpm, the homogenizing time is 5min, the high-pressure homogenizing pressure is 800bar, and homogenizing is carried out for 3-5 times.
(5) And (3) closing the high-pressure homogenizer, and taking a small amount of finished products for observation, wherein the appearance is colorless, the fluidity and the dispersibility are good, and the oleanolic acid nanoemulsion is obtained if the appearance is obvious in opalescence.
Example 3:
the 5% oleanolic acid nanoemulsion comprises the following raw material components in percentage by weight as shown in table 3:
TABLE 3 Table 3
Component (A) | Weight percent (%) |
Oleanolic acid | 5 |
Eucalyptus oil | 12 |
Tea tree oil | 8 |
Diethylene glycol monoethyl ether (Transcutol) | 36 |
PEG-8 caprylic/capric glyceride | 36 |
Distilled water | 3 |
The preparation method comprises the following steps:
(1) the eucalyptus oil, tea tree oil, diethylene glycol monoethyl ether (Transcutol) and PEG-8 caprylic/capric glyceride with the formula amounts are weighed and added into a container A to be uniformly mixed.
(2) And (3) adding oleanolic acid with the formula amount into the mixture, and heating and stirring in a water bath at 60 ℃ until the oleanolic acid is completely dissolved.
(3) Distilled water was added to vessel B, and then the mixture of vessel a was slowly added to vessel B with stirring to obtain a primary emulsion.
(4) And then using a high-pressure homogenizing and emulsifying device to perform secondary emulsification, wherein the homogenizing speed is 4000rpm, the homogenizing time is 3min, the high-pressure homogenizing pressure is 800bar, and the homogenizing is performed for 3-5 times.
(5) And (3) closing the high-pressure homogenizer, and taking a small amount of finished products for observation, wherein the appearance is colorless, the fluidity and the dispersibility are good, and the oleanolic acid nanoemulsion is obtained if the appearance is obvious in opalescence.
Example 4:
the oleanolic acid nanoemulsion for promoting hair growth comprises the following raw material components in percentage by weight as shown in table 4:
TABLE 4 Table 4
Component (A) | Weight percent (%) |
Oleanolic acid | 1 |
Oleuropein | 1.6 |
Baicalin | 0.5 |
Tea tree oil | 2 |
Eucalyptus oil | 1 |
Rosemary essential oil | 1.2 |
Peppermint essential oil | 1.6 |
Lavender essential oil | 0.4 |
Cedar essential oil | 0.2 |
1,2 pentanediol | 5 |
Diethylene glycol monoethyl ether (Transcutol) | 23 |
Astragalus polysaccharides | 1 |
EDTA-4Na | 0.1 |
Para hydroxy acetophenone | 0.3 |
Arginine (Arg) | 0.6 |
Polyoxyethylene 30 castor oil | 7 |
Tween 80 | 12 |
Polyoxyethylene 40 hydrogenated castor oil | 16 |
Distilled water | 25.5 |
The preparation method comprises the following steps:
(1) the eucalyptus oil, tea tree oil, peppermint essential oil, lavender essential oil, rosemary essential oil, cedar essential oil, dipropylene glycol and diethylene glycol monoethyl ether (Transcutol) are respectively weighed according to the formula amount and uniformly mixed in a container A.
(2) Weighing polyoxyethylene 30 castor oil, tween 80 and polyoxyethylene 40 hydrogenated castor oil, mixing, adding into the mixture of container A, adding oleanolic acid and baicalin, heating in 80deg.C water bath, and stirring to dissolve completely.
(3) Adding distilled water into container B, adding oleuropein and/or Astragalus polysaccharides, EDTA-4Na, arginine and p-hydroxyacetophenone, and stirring to dissolve.
(4) Adding the mixture of the container A into the container B under stirring to obtain primary emulsion, and then emulsifying for the second time by using a high-pressure homogenizing emulsifying device, wherein the homogenizing speed is 5000rpm, the homogenizing time is 5min, the high-pressure homogenizing pressure is 800bar, and homogenizing is carried out for 3-5 times.
(5) And (3) closing the high-pressure homogenizer, and taking a small amount of finished products for observation, wherein the appearance is brown, semitransparent, fluid and dispersive, and the oleanolic acid nanoemulsion is obtained when the oleanolic acid nanoemulsion has obvious visible opalescence.
Example 5:
the oleanolic acid skin care nanoemulsion comprises the following raw material components in percentage by weight as shown in table 5:
TABLE 5
Component (A) | Weight percent (%) |
Oleanolic acid | 0.5 |
Oleuropein | 1 |
Baicalin | 0.2 |
Tea tree oil | 0.7 |
Uganli essential oil | 0.5 |
Peppermint essential oil | 1.2 |
Peppermint essential oil | 0.5% |
Lemon essential oil | 0.2% |
1, 2-hexanediol | 3 |
Dipropylene glycol | 3 |
Diethylene glycol monoethyl ether (Transcutol) | 8 |
PEG-8 caprylic/capric glyceride | 12 |
Polyoxyethylene 40 hydrogenated castor oil | 15 |
Glyceryl monostearate | 3 |
Sodium hyaluronate | 1 |
Vitamin C | 0.7 |
Aloe vera gel | 0.3 |
Phenoxyethanol | 0.3 |
EDTA-2Na | 0.1 |
Distilled water | 57 |
The preparation method comprises the following steps:
(1) tea tree oil, uganli essential oil, lemon essential oil, 1, 2-hexanediol, dipropylene glycol and diethylene glycol monoethyl ether (Transcutol) are weighed according to the formula amount respectively and uniformly mixed in a container A.
(2) The polyoxyethylene 30 castor oil, the Tween 80 and the polyoxyethylene 40 hydrogenated castor oil with the formula amounts are weighed and added into the mixture of the container A, and then oleanolic acid and baicalin are added and placed in a water bath with the temperature of 60 ℃ for heating and stirring until the mixture is completely dissolved.
(3) Adding distilled water into container B, adding oleuropein, phenoxyethanol, EDTA-2Na, and vitamin C, stirring to dissolve, adding sodium hyaluronate and aloe gel, standing for 24 hr, and swelling.
(4) Adding the mixture of the container A into the container B under stirring to obtain primary emulsion, and then emulsifying for the second time by using a high-pressure homogenizing emulsifying device, wherein the homogenizing speed is 6000rpm, the homogenizing time is 5min, the high-pressure homogenizing pressure is 800bar, and homogenizing is 3-5 times.
(5) And (3) closing the high-pressure homogenizer, and taking a small amount of finished products for observation, wherein the appearance is light yellow, semitransparent, good in fluidility and dispersibility, and obvious in visible opalescence, namely the oleanolic acid nanoemulsion.
Example 6:
the oleanolic acid acne-removing nanoemulsion gel comprises the following raw material components in percentage by weight as shown in table 6:
TABLE 6
The preparation method comprises the following steps:
(1) the tea tree oil, the peppermint essential oil, the rosemary essential oil, the cedar essential oil, the 1, 3-butanediol and the diethylene glycol monoethyl ether (Transcutol) with the formula amounts are respectively weighed and uniformly mixed in a container A.
(2) Weighing polyoxyethylene 35 castor oil and tween 80, adding into the mixture of container A, adding oleanolic acid and baicalin, heating in 80deg.C water bath, and stirring to dissolve completely.
(3) Distilled water is added into a container B, phenoxyethanol, EDTA-2Na and dipotassium glycyrrhizinate are added, and stirring is carried out until dissolution.
(4) Adding the mixture of the container A into the container B under stirring to obtain primary emulsion, then emulsifying for the second time by using a high-pressure homogenizing emulsifying device, wherein the homogenizing speed is 4000rpm, the homogenizing time is 6min, the high-pressure homogenizing pressure is 800bar, and homogenizing for 3-5 times to obtain the nanoemulsion.
(5) Slowly adding carbomer 940 into the nanoemulsion under stirring, adding triethanolamine, and standing at normal temperature for 24 hr to fully swell carbomer 940 to obtain transparent or semitransparent olea acne-removing nanoemulsion gel.
The product appearance of the oleanolic acid nanoemulsion compositions prepared in examples 1 to 6 is shown in fig. 1.
Test example 1: effect experiment of oleanolic acid nanoemulsion on androgen alopecia model mice
1.1 laboratory animals
40 male C57BL/6 mice are selected, and the weight is 16-18 g, and the age is 3-4 weeks. All rats are placed in an animal house with proper temperature and humidity for feeding, and ventilation is carried out for 1-2 times a day, and each time is 1h. Daily 12 hours of day and night alternation was ensured while keeping quiet and avoiding other disturbances. Ensuring that the mice have enough activity space. The mice are fed with the maintenance feed, purified water is used as drinking water for the rats, and the drinking water and the feed are replaced every day, so that the ventilation, the sanitation and the sanitation of the living environment of the animals are maintained. Illumination is carried out in the daytime (12+/-2) h, the indoor temperature (20+/-2) DEG C and the relative humidity is 40% -60%.
1.2 grouping
40 rats were randomly divided into 5 groups, group 1: blank control 8; group 2: model group 8; group 3: minoxidil group 8; group 4: 8 oleanolic acid groups; group 5: oleanolic acid + oleuropein + baicalin group 8.
1.3 Experimental drugs
The minoxidil group used a commercially available 5% minoxidil solution; the nanoemulsion prepared in example 1 was used for the oleanolic acid group, and the nanoemulsion prepared in example 4 was used for the oleanolic acid, oleuropein and baicalin group.
1.4 moulding
All mice were injected subcutaneously 1 time per day on the back with testosterone propionate at a dose of 5 mg/kg/day for 4 weeks, except for the placebo group, which was injected with an equivalent amount of physiological saline at the same location on the back of the mice.
1.5 administration
After the 4-week molding is successful, normal saline is injected into the blank control group in a subcutaneous mode, testosterone propionate is injected into the other groups continuously for 4 weeks, and the androgen level in the mice is maintained. The model group only continues to inject testosterone propionate 5 mg/kg/day, group 3 uniformly smears 5% minoxidil after each injection of testosterone propionate for 1h, group 4 smears 1% oleanolic acid nanoemulsion prepared in example 1, and group 5 smears oleanolic acid nanoemulsion composition prepared in example 4.
1.6 observations of laboratory animals
1.6.1 general State observation
The unhairing degree of each group of rats is observed every day, and the local skin reactions such as red swelling, edema, liquid seepage and the like do not appear in the medicine smearing area.
1.6.2 preparation of skin tissue sections
After 8 weeks of experiment, the back dehairing area of each group of mice was selected, the parallel spinal column was sampled to about 1x 1m2, and 3 skin tissue sections of substantially the same area were sampled per mouse. Specimens were prepared according to the conventional skin histopathological process, paraffin embedded, sectioned, HE stained, observed under a microscope for morphological changes in hair follicles of mice and counted for total hair follicle number in 100 fields, and the average of three sections was taken for relevant statistical analysis, and the data were expressed as x±sd. When p <0.05, the difference is significant, and has statistical significance.
1.7 experimental results
1.7.1 section follicular observation and follicular counting
Observing the cross section condition of skin hair follicles, and after the external application of the medicine for 4 weeks, the hair of a blank control group is complete and dense, and black and glossy; the area of alopecia of the model group is obviously increased compared with that of the blank group; both minoxidil group and group 3, group 4 mice showed significantly reduced areas of hair loss compared to the model group, see figure 2.
TABLE 7 comparison of follicle count for each group
Group of | Total hair follicle count |
Blank control group (group 1) | 38.75±4.12 |
Model group (group 2) | 13.31±3.42* |
Minoxidil group (group 3) | 30.38±8.32 # |
Oleanolic acid set (set 4) | 31.63±6.73 & |
Oleanolic acid + oleuropein + baicalin group (group 5) | 34.12±8.85 #$ |
Note that p compared to the blank control group<0.05; # Compared with the molding group, p<0.05;&Compared with minoxidil group, p>0.05; $ Compared with minoxidil group, p<0.05。
As can be seen from table 7, oleanolic acid group (group 4) had clear therapeutic effect on androgenic alopecia model mice, and there was no significant statistical difference (P > 0.05) in effect compared to 5% minoxidil group effect; the combined effect of group 4 oleanolic acid + oleuropein + baicalin on promoting hair growth and reducing hair loss in Yu Xiong hormonal hair loss mice was superior to minoxidil group (P <0.05, table 7).
Test example 2 stability investigation of oleanolic acid nanoemulsion formulations
1) Influence of centrifugal acceleration test on nanoemulsion stability
Taking the prepared nano emulsion, centrifuging at 20000r/min, observing that the appearance of the nano emulsion is still clear and transparent after 15min, and avoiding the phenomenon of oil-water delamination.
2) Light stability test
The nanoemulsion of the invention is properly filled into a glass bottle, and is placed at room temperature under the illumination condition of (5000+/-500) lx after being sealed, and is respectively sampled and observed for 1d, 3d and 7 d. The result shows that the nanoemulsion keeps clear and transparent appearance, and has no phenomena of layering, demulsification and the like.
3) Sample retention observation test
The emulsion of the invention is packaged in glass bottles, sealed and then is respectively placed at the temperature of 4 ℃, 25 ℃ and 40 ℃ for sample reserving and inspection for 6 months, and the samples are taken and observed every 14 d. The results show that the emulsion keeps clear and transparent appearance under the four temperature conditions, and no phenomena such as layering and demulsification are seen.
Test example 3: animal skin irritation investigation of oleanolic acid nanoemulsion formulations
New Zealand white rabbits are more responsive to irritants than humans. Skin irritation experiments were performed on examples 4 to 6 by taking 12 healthy New Zealand white rabbits, each half of male and female, and dividing them into 4 groups of 3 each, each half of male and female. The animals were dehaired on both sides of the spinal column 24h before dosing with an electric razor and the dehairing area was 5 x 5cm. The skin irritation test results of the animal are non-irritating, which indicates that oleanolic acid essential oil nanoemulsion and nanoemulsion gel have no obvious irritation to New Zealand white rabbits.
Test example 4: solubilization of oleanolic acid by essential oils
Adding appropriate amount of oleanolic acid into 5mL centrifuge tube, adding 1g of each adjuvant respectively, performing ultrasonic treatment for 30min, balancing at 60deg.C under 100r/min, centrifuging for 10min at 10000r/min, collecting supernatant, diluting filtrate with methanol to appropriate ratio, and performing HPLC to calculate oleanolic acid content in each adjuvant.
The solubility of oleanolic acid in different solvents is shown in Table 8, and from Table 8, the solubility of the oleanolic acid in the essential oil is far higher than that of the common solvents, and the combination of the essential oil and the cosurfactant has better solubilization and dissolution assisting effects on the oleanolic acid.
Table 8: oleanolic acid solubility (mg/ml) of different solvents
Experiments have demonstrated that the topical compositions of the present invention can be used in the preparation of products for the treatment and control of adverse effects of skin conditions including, but not limited to, androgenic alopecia, telogen effluvium, alopecia areata, or other types of alopecia, acne, seborrheic dermatitis, folliculitis, skin aging, and other skin conditions.
The oleanolic acid nanoemulsion composition can be applied to cosmetics and can be used for skin care, hair care and the like.
The oleanolic acid nanoemulsion composition can be used as a dosage form for caring skin or hair by adding an excipient, and can be used independently as a product or mixed with other cosmetics or medicine raw materials to prepare nanoemulsion gel, ointment, cream, emulsion, spray, lotion, liniment, patch or coating.
The oleanolic acid nanoemulsion composition of the present invention can be made into products including, but not limited to, hair growth lotion, hair care essence, skin care gel, shampoo, hair conditioner, mascara, mask, face cream, and lotion.
The above-described embodiments are merely preferred embodiments of the present invention and should not be construed as limiting the scope of the present invention. All equivalent changes and modifications within the scope of the present invention are intended to be covered by the present invention.
Claims (8)
1. The high-concentration oleanolic acid nanoemulsion composition is characterized by comprising the following components in percentage by weight:
0.5 to 2 percent of oleanolic acid, 10 to 30 percent of surfactant, 10 to 25 percent of cosurfactant, 1 to 10 percent of terpene-containing essential oil, 0.1 to 1 percent of baicalin, 0.5 to 2 percent of oleuropein, a proper amount of additive and the balance of water; the terpene-containing essential oil is selected from at least five of eucalyptus oil, tea tree essential oil, cedar essential oil, peppermint essential oil, lavender essential oil and rosemary essential oil;
the surfactant is at least one selected from PEG-6 caprylic acid/capric acid glyceride, PEG-8 caprylic acid/capric acid glyceride, tween 80, tween 20, polyoxyethylene castor oil, span 80, glyceryl monostearate, lecithin, stearyl alcohol polyether and polyethylene glycol stearate;
The cosurfactant is at least one selected from diethylene glycol monoethyl ether, dipropylene glycol, 1, 3-butanediol, ethanol, 1, 2-pentanediol, 1, 2-hexanediol, propylene glycol, glycerol and polyethylene glycol.
2. The high-concentration oleanolic acid nanoemulsion composition of claim 1, wherein the oleanolic acid is pure or a plant extract containing oleanolic acid; the plant extract contains at least 2% oleanolic acid, and is selected from one of fructus Ligustri Lucidi extract, herba Swertiae Mileensis extract, and fructus Oleae Europaeae extract;
the HLB value of the surfactant is 8-18.
3. The high-concentration oleanolic acid nanoemulsion composition of claim 1, characterized in that the terpene-containing essential oil comprises, by weight, 0.2% -10% of eucalyptus oil, 0.2% -10% of tea tree essential oil, 0.3% -5% of cedar essential oil, 0.8% -3.2% of peppermint essential oil, 0.6% -2.4% of lavender essential oil and 0.5% -3.2% of rosemary essential oil.
4. The high concentration oleanolic acid nanoemulsion composition of claim 1, characterized in that the additive comprises at least one of a thickener, a humectant, a pH adjustor, a preservative, an antioxidant, a conditioner, a chelating agent, an ultraviolet absorber, a nutritional agent, an emollient, an antiandrogen agent, a hair tonic;
The thickener is selected from carbomer, hydroxyethyl cellulose, sodium carboxymethylcellulose, sodium alginate, polycarbophil, poloxamer, xanthan gum, aloe gum, guar gum, polyquaternary ammonium salt Q-10, acrylic acid and acrylic ester; the usage amount of the thickener is 0.1% -5% of the total weight of the nanoemulsion;
the humectant is at least one selected from astragalus polysaccharide, sodium hyaluronate, dipotassium glycyrrhizinate, glycerol, polyethylene glycol, sorbitol, maltitol, aloe vera gel, sodium lactate and squalane; the usage amount of the humectant is 0.5% -5% of the total weight of the nanoemulsion;
the pH adjustor is selected from the group consisting of citric acid, malic acid, lactic acid, phosphoric acid, triethanolamine, and combinations thereof; the usage amount of the pH regulator is 0.1% -1% of the total weight of the nanoemulsion;
the preservative is selected from p-hydroxyacetophenone, phenoxyethanol, benzoic acid, octanoyl hydroxamic acid, octanoyl glycol, methyl hydroxybenzoate, ethyl hydroxybenzoate, propyl hydroxybenzoate, butyl hydroxybenzoate, dimethylaminoethanol, benzalkonium chloride and benzalkonium bromide, and the use amount of the preservative is 0.1-0.6% of the total weight of the nanoemulsion;
the antioxidant is one or more selected from sodium bisulphite, vitamin E, vitamin C, lauryl gallate, propyl gallate, phenethyl caffeate, arbutin, ferulic acid, magnesium ascorbyl phosphate, sodium ascorbyl phosphate and ascorbyl ethyl ether;
The conditioner is one or more of allantoin, dipotassium glycyrrhizinate, tocopheryl acetate, olive leaf extract, radix Scutellariae extract, lavender extract, chamomile extract, witch hazel extract, purslane extract, gentian root extract and rosemary extract;
the chelating agent is selected from EDTA, EDTA-2Na or EDTA-4Na;
the ultraviolet absorbent is at least one selected from baicalin derivatives, quercetin derivatives, p-aminobenzoic acid derivatives, salicylic acid derivatives, benzophenone derivatives, diphenyl acrylate and cinnamic acid derivatives;
the nutritional agent is at least one selected from lysine, cystine, arginine, collagen, biotin, chondroitin sulfate, keratan sulfate, heparin sulfate, vitamins A, B1, B2, B6, E, C and vitamin C derivatives;
the emollient is selected from cetostearyl alcohol, lanolin, isopropyl isostearate, vaseline, liquid paraffin, polydimethylsiloxane, dimethiconol, simethicone, shea butter, cetyl isooctanoate, natural squalane, octyl methoxycinnamate;
the antiandrogen agent is at least one selected from finasteride, dutasteride, irinotecan, bicalutamide, equol, saw palmetto extract, kuh-seng extract, red sage extract, lavender extract, turmeric extract, emblic extract, nettle extract, garden balsam extract, ganoderma lucidum extract, dittany bark extract, tea tree extract, kudzu root extract, baical skullcap root extract, cimetidine, cyproterone, diethylstilbestrol, 11-alpha-hydroxyprogestrel, norgestrel, levonorethindrone, norethindrone;
The pilatory is selected from at least one of Polygoni Multiflori radix extract, fructus Ligustri Lucidi extract, carthami flos extract, platycladi extract, herba Rosmarini officinalis extract, ginseng radix extract, notoginseng radix extract, green tea extract, herba Centellae extract, herba Swertiae Mileensis extract, semen Pisi Sativi extract, ginsenoside, radix Angelicae sinensis extract, folium Oleae Europaeae extract, radix astragali extract, rhizoma Ligustici Chuanxiong extract, rhizoma Zingiberis recens extract, semen Sesami Niger extract, semen Cuscutae extract, ecliptae herba extract, and folium Mori extract.
5. The high concentration oleanolic acid nanoemulsion composition of claim 1, wherein the water is selected from distilled water, purified water, or deionized water.
6. The method for preparing the oleanolic acid nanoemulsion composition of claim 1, characterized by comprising the steps of:
1) Adding a formula amount of cosurfactant and terpene-containing essential oil into a container A, and uniformly mixing and stirring; adding surfactant with formula amount, and mixing; then adding oleanolic acid with formula amount, and further adding baicalin with other fat-soluble components, stirring until completely dissolving;
2) Adding water with a formula amount into a container B, and further adding a proper amount of additives to obtain a water phase;
3) Slowly adding the mixture of the container A into the water phase of the container B while stirring to obtain primary emulsion;
4) And 3) performing high-speed shearing emulsification on the primary emulsion prepared in the step 3), and performing secondary emulsification by using a high-pressure homogenizing and emulsifying device, so that the oleanolic acid nanoemulsion composition is obtained after full emulsification.
7. The method for preparing the oleanolic acid nanoemulsion composition of claim 6, characterized in that in step 1), the mass ratio of the cosurfactant to the terpene-containing essential oil is 4:1 to 1:1; the dissolution is to stir at normal temperature of 25-40 ℃ until the dissolution is complete, or to stir at 40-80 ℃ in water bath condition until the dissolution is complete;
in the step 4), the high-pressure homogenizing and emulsifying device is used for secondary emulsification, the homogenizing speed is 4000-10000 rpm, the homogenizing time is 3-10 min, the high-pressure homogenizing pressure is 800-1000 bar, and the homogenizing is carried out for 3-5 times; the average particle diameter of the liquid drops in the prepared oleanolic acid nanoemulsion composition is 10-200 nm; the secondary emulsification adopts micro-jet emulsification or ultrasonic emulsification.
8. The use of the oleanolic acid nanoemulsion composition of claim 1 in the preparation of cosmetics; the cosmetic includes, but is not limited to, hair tonic, shampoo, gel, perfume, hair wax, hair conditioner, hair mask, mascara, hair oil, hair conditioner, hair blackening agent, hair dye, hair gel, hair mousse;
The oleanolic acid nanoemulsion composition is used in cosmetics for improving or preventing alopecia, sparse hair and white hair; the alopecia comprises androgenetic alopecia and telogen alopecia;
the oleanolic acid nanoemulsion composition is used for hair care;
the oleanolic acid nanoemulsion composition is added with an excipient to be used as a dosage form for hair care, and the oleanolic acid nanoemulsion composition is used alone as a product or is mixed with other cosmetic raw materials to prepare an oleanolic acid nanoemulsion gel, an ointment, an emulsion, a spray, a lotion, a patch or a coating dosage form.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110419745.1A CN115607510B (en) | 2021-04-19 | 2021-04-19 | High-concentration oleanolic acid nanoemulsion composition and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110419745.1A CN115607510B (en) | 2021-04-19 | 2021-04-19 | High-concentration oleanolic acid nanoemulsion composition and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115607510A CN115607510A (en) | 2023-01-17 |
CN115607510B true CN115607510B (en) | 2024-03-08 |
Family
ID=84855020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110419745.1A Active CN115607510B (en) | 2021-04-19 | 2021-04-19 | High-concentration oleanolic acid nanoemulsion composition and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115607510B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116785215B (en) * | 2023-08-28 | 2023-12-19 | 吉林大学 | Ginseng extract composition nano system and preparation method and application thereof |
CN118178278A (en) * | 2024-03-12 | 2024-06-14 | 江苏省连云港中医药高等职业技术学校 | Chinese and western combined hair-growing massage nanoemulsion and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101991532A (en) * | 2009-08-14 | 2011-03-30 | 上海开拓者医药发展有限公司 | Self-microemulsion composition, microemulsion and preparation methods thereof |
-
2021
- 2021-04-19 CN CN202110419745.1A patent/CN115607510B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101991532A (en) * | 2009-08-14 | 2011-03-30 | 上海开拓者医药发展有限公司 | Self-microemulsion composition, microemulsion and preparation methods thereof |
Non-Patent Citations (3)
Title |
---|
Oleanolic Acid Alters Multiple Cell Signaling Pathways: Implication in Cancer Prevention and Therapy;Lovro Žiberna等;《Int J Mol Sci.》;20170316;第18卷(第3期);643 * |
中草药治疗雄激素性秃发的实验研究进展;朱红柳等;《临床皮肤科杂志》;第46卷(第11期);摘要、第2节 * |
胡容峰.《工业药剂学》.2010,414-418. * |
Also Published As
Publication number | Publication date |
---|---|
CN115607510A (en) | 2023-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113230172B (en) | Cosmetic or dermatological composition, preparation method and application thereof | |
CN108201513B (en) | Hair composition and hair restorer | |
EP2094286B1 (en) | Compositions and methods of inducing hair growth utilizing continus coggygria | |
MX2008012654A (en) | Novel compositions for hair disorders and process of preparation thereof. | |
CN114796000A (en) | Micro-emulsified composition of oleanolic acid and preparation method and application thereof | |
CN115607510B (en) | High-concentration oleanolic acid nanoemulsion composition and preparation method thereof | |
CN110787088A (en) | Basic composition for lip wrinkle fading and preparation method and application thereof | |
WO2001074326A1 (en) | Agents improving skin barrier function | |
JP2008143784A (en) | Cell growth promoter | |
TWI703988B (en) | Methods and compositions for enhancing hair quality using blackberry extract | |
JP2011236156A (en) | Collagen production promoter | |
CN105267261A (en) | Plant extract combination having skin repair promoting and healing promoting function | |
CN112870127B (en) | Herbal composition rich in ginseng essence and capable of repairing sensitive skin and preparation method of herbal composition | |
JP3974003B2 (en) | Hair growth material and external preparation for skin containing the same | |
JP2011046646A (en) | Antioxidant and skin external preparation | |
KR101363028B1 (en) | A cosmetic composition for the prevention, improvement or treatment of acne vulgaris comprising the mixture of extract of Melissa officinalis, Citrus bergamia, leaves of Mentha arvensis, Eclipta prostrata and Hovenia dulcis Thunb | |
JP2002179584A (en) | TESTOSTERONE 5alpha-REDUCTASE INHIBITOR AND ANDROGEN RECEPTOR BINDING INHIBITOR, HAIR AGENT AND SKIN COSMETIC | |
JP5795146B2 (en) | Moisturizer and external preparation for skin | |
JP3382148B2 (en) | External preparation for head | |
JP2006257059A (en) | Androgen receptor binding inhibitor, agent for hair and skin care preparation for dermal use formulated with the same | |
JP5116428B2 (en) | Moisturizer and external preparation for skin | |
JPH08231352A (en) | Hair tonic | |
CN107260811B (en) | Skin care/treatment composition with acne prevention and treatment effects | |
JP2009057309A (en) | Skin preparation for external use and humectant | |
JPH07277930A (en) | Hair growth material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Country or region after: China Address after: 2nd Floor, No. 53 Banmei Road, Jinjiang City, Fujian Province, 362200 Applicant after: Quanzhou Daxun Biotechnology Co.,Ltd. Address before: 362200 No. 1302, A3, building 6, Huijing City, Shuanggou community, Meiling street, Jinjiang City, Quanzhou City, Fujian Province Applicant before: Quanzhou Daxun Biotechnology Co.,Ltd. Country or region before: China |
|
GR01 | Patent grant | ||
GR01 | Patent grant |